Eyenovia, Inc. (EYEN)
| Market Cap | 115.59M |
| Revenue (ttm) | 10.00M |
| Net Income (ttm) | -18.90M |
| Shares Out | 36.12M |
| EPS (ttm) | -0.55 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 125,816 |
| Open | 3.25 |
| Previous Close | 3.20 |
| Day's Range | 3.15 - 3.29 |
| 52-Week Range | 1.50 - 3.34 |
| Beta | 1.66 |
| Analysts | Buy |
| Price Target | 14.62 (+355.45%) |
| Earnings Date | May 10, 2023 |
About EYEN
Eyenovia, Inc., a clinical stage ophthalmic company, engages in developing therapeutics based on its proprietary microdose array print platform technology. The company focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. It focuses on the development of therapeutic indications for patients with progressive myopia and age-related near vision impairment or presbyopia indications; and microdose fixed combination ophthalmic pharmaceutical for mydria... [Read more]
Financial Performance
In 2021, Eyenovia's revenue was $14.00 million, an increase of 600.00% compared to the previous year's $2.00 million. Losses were -$12.78 million, -35.36% less than in 2020.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for EYEN stock is "Buy." The 12-month stock price forecast is $14.62, which is an increase of 355.45% from the latest price.
News
Eyenovia to Report Fourth Quarter and Full-Year 2022 Results on Thursday, March 30
Company to host an investor conference call and webcast at 4:30 pm ET Company to host an investor conference call and webcast at 4:30 pm ET
Eyenovia Announces Independent Director Stephen Benjamin to Step Down to Assume Role of Head of White House's Office of Public Engagement
NEW YORK, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in connection with its ow...
Eyenovia Announces Development Collaboration Agreement with Formosa Pharmaceuticals
Collaboration will combine Eyenovia's Optejet® dispensing technology with Formosa's APNT™ nanoparticle formulation platform for the potential development of new topical therapeutics in high-value opht...
Formosa Pharmaceuticals Announces Development Collaboration Agreement with Eyenovia
The collaboration will combine Formosa's proprietary APNT™ nanoparticle formulation platform with Eyenovia's Optejet® dispensing technology for the development of new ophthalmic therapies in high-valu...
Eyenovia Reveals Positive Evidence That Optejet® Delivery Technology Decreased Inflammation From Preserved Glaucoma Solutions Compared to Drops
Academic study found the Optejet® to be comparable to non-preserved drops in lessening the proinflammatory response Academic study found the Optejet® to be comparable to non-preserved drops in lesseni...
Eyenovia Announces Participation at the 2023 International Consumer Electronics Show
Booth to feature “smart” remote patient monitoring capabilities being developed for future versions of the company's novel Optejet® drug delivery technology
Eyenovia Announces FDA Acceptance of New Drug Application for MydCombi™ for In-Office Pupil Dilation
Agency assigns PDUFA action date of May 8, 2023
Eyenovia Announces Promotion of Bren Kern to Chief Operating Officer and Corporate Vice President
Company also announces that Julia Haller, MD, is stepping down from its Board of Directors Company also announces that Julia Haller, MD, is stepping down from its Board of Directors
Eyenovia Announces $15 Million Credit Facility with Avenue Venture Debt Fund
Transaction proceeds, together with cash on-hand, expected to fund operations through late 2023/early 2024, including potential FDA approval of MydCombi™ Transaction proceeds, together with cash on-ha...
Eyenovia to Present at Upcoming BTIG Ophthalmology Day
NEW YORK, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (Nasdaq: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its o...
Eyenovia Reports Third Quarter 2022 Financial Results and Provides Business Update
Announced positive results from the second Phase 3 study of MicroLine in presbyopia, VISION-2; Company planning to meet with the FDA to gain alignment on regulatory path forward as a drug/device combi...
Eyenovia to Report Third Quarter 2022 Results on Thursday, November 10
Company to host an investor conference call and webcast at 4:30pm ET on that day Company to host an investor conference call and webcast at 4:30pm ET on that day
Eyenovia to Present at the American Academy of Optometry's Annual Meeting
NEW YORK, Oct. 21, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its o...
Eyenovia Announces Positive Results from VISION-2 Phase 3 Study of MicroLine as a Potential On-Demand Treatment for Presbyopia
NEW YORK, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its o...
Eyenovia Announces Planned Retirement of Lead Independent Director Ken Lee, Jr.
NEW YORK, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its ...
Eyenovia to Present at Upcoming Healthcare Conferences
NEW YORK, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (Nasdaq: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array ...
Eyenovia to Participate in Multiple Medical Meetings in September
NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of late-stage microdose array print (MAP™) therapeutic...
Eyenovia Reports Second Quarter 2022 Financial Results
Announced appointment of Michael Rowe as Chief Executive Officer and Board member
Eyenovia to Report Second Quarter 2022 Results on Wednesday, August 10
Company to host an investor conference call and webcast at 4:30pm ET on that day Company to host an investor conference call and webcast at 4:30pm ET on that day
Eyenovia Announces Appointment of Ophthalmic Industry Veteran Michael Rowe as Chief Executive Officer and Board Member
Appointment of Mr. Rowe, Eyenovia's current Chief Operating Officer, maintains continuity while bringing significant ophthalmic industry, operations and commercialization expertise to the CEO role App...
Eyenovia Provides Manufacturing Update and Announces Appointment of Bren Kern as SVP of Manufacturing and Operations
New internal manufacturing capabilities to complement existing contract manufacturing relationships New internal manufacturing capabilities to complement existing contract manufacturing relationships
Eyenovia Announces Appointments of Dr. Ellen Strahlman and Dr. Ram Palanki as New and Independent Members of its Board of Directors
NEW YORK, July 07, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (Nasdaq: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of late-stage microdose array print (MAP™) therapeutics...
Eyenovia Strategic Partner Arctic Vision Enrolls First Patient in Phase III Clinical Trial of ARVN003 (MicroLine) for Presbyopia in China
Arctic Vision also licensed and is developing Eyenovia's programs for pediatric progressive myopia (MicroPine) and pharmacologic mydriasis (MydCombi™) in Greater China and South Korea Arctic Vision al...
UPDATE: Eyenovia Announces Virtual 2022 Annual Meeting of Stockholders
NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) investigational product...
Eyenovia Announces Virtual 2022 Annual Meeting of Stockholders
NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) investigational product...